Journal
BIOMEDICINES
Volume 9, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines9010083
Keywords
B cells; autoimmunity; self-antigen; antigen-specific therapies; tolerance; B lymphocytes; anergy
Categories
Funding
- NIH [K01 OD028759, P30 DK116073]
Ask authors/readers for more resources
Targeted therapies focusing on autoantigen-specific B cells have shown potential for more precise treatment of autoimmune disorders, while also presenting challenges that need to be addressed for their clinical applicability.
B lymphocytes play critical roles in the development of autoimmunity, acting as autoantibody manufacturers, antigen-presenting cells, and producers of cytokines. Pan-B cell depletion has demonstrated efficacy in treatment of many autoimmune disorders, but carries with it an unfavorable safety profile due to global immune suppression. Hence, attention has turned to the potential of autoantigen-specific B cell targeted therapies, which would deplete or silence pathogenic self-antigen-reactive cells while sparing B cells needed for immune defense. Here, we discuss the antigen-specific B cell-targeted approaches that are under development or are under consideration, that could be employed to allow for more precise therapy in the treatment of autoimmunity. Lastly, we discuss some of the challenges associated with antigen-specific B cell targeting that may impact their clinical applicability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available